Aspira Women's Health: Leadership Changes Announced
Ticker: AWHL · Form: 8-K · Filed: Mar 25, 2024 · CIK: 926617
Sentiment: neutral
Topics: leadership-change, officer-departure, board-election
TL;DR
Aspira Women's Health CMO out, new directors in, compensation changes filed.
AI Summary
Aspira Women's Health Inc. announced on March 20, 2024, the departure of its Chief Medical Officer, Dr. Michael W. Nolen. The company also reported on the election of new directors and changes in officer compensation arrangements. This filing details the transition in leadership and potential shifts in executive compensation.
Why It Matters
Changes in key executive positions and compensation can signal strategic shifts or financial adjustments within the company, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Departures of key officers and changes in board composition can introduce uncertainty regarding the company's strategic direction and operational stability.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Dr. Michael W. Nolen (person) — Chief Medical Officer (departing)
- March 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
Who has departed from Aspira Women's Health Inc. as of March 20, 2024?
Dr. Michael W. Nolen, the Chief Medical Officer, has departed from Aspira Women's Health Inc.
What other items are reported in this 8-K filing?
The filing also reports on the election of directors and compensatory arrangements of certain officers.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is March 20, 2024.
In which state is Aspira Women's Health Inc. incorporated?
Aspira Women's Health Inc. is incorporated in Delaware.
What is the SIC code for Aspira Women's Health Inc.?
The Standard Industrial Classification (SIC) code for Aspira Women's Health Inc. is 2835, for IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 665 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-03-22 20:22:03
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
- $50,000 — k will be eligible for a bonus of up to $50,000 upon the closing of one or more equity
- $3,000,000 — ggregate net proceeds to the Company of $3,000,000 or more during the Hombeck Amendment Te
- $100,000 — ndment Term. The bonus will increase to $100,000 upon the aggregate closing of one or mo
- $5,000,000 — in total net proceeds to the Company of $5,000,000 or more during the Hombeck Amendment Te
Filing Documents
- d772861d8k.htm (8-K) — 25KB
- d772861dex101.htm (EX-10.1) — 9KB
- 0001193125-24-075570.txt ( ) — 161KB
- awh-20240320.xsd (EX-101.SCH) — 3KB
- awh-20240320_lab.xml (EX-101.LAB) — 18KB
- awh-20240320_pre.xml (EX-101.PRE) — 11KB
- d772861d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: March 22, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer